Ovarian cancer

@article{Jayson2014OvarianC,
  title={Ovarian cancer},
  author={Gordon C. Jayson and Elise C. Kohn and Henry C Kitchener and Jonathan A. Ledermann},
  journal={The Lancet},
  year={2014},
  volume={384},
  pages={1376-1388}
}
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with… Expand
Epithelial ovarian cancer
TLDR
Urgent progress is needed to develop evidence and consensus-based treatment guidelines for each subgroup, and requires close international cooperation in conducting clinical trials through academic research groups such as the Gynecologic Cancer Intergroup. Expand
Management and Treatment of Recurrent Epithelial Ovarian Cancer.
TLDR
New targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. Expand
Early onset neutropenia: a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer
TLDR
Early onset neutropenia may be potentially used as a potential indicator for chemosensitivity and favorable prognosis of SOC in patients who underwent six cycles of carboplatin plus paclitaxel adjuvant chemotherapy following primary cytoreductive surgery. Expand
Honokiol and Magnolol Induce Apoptosis and Cell Cycle Arrest in Human Ovarian Cancer Cells
Epithelial ovarian cancer is the fourth most common cause of cancer-related death among women worldwide. Over 220,000 woman are diagnosed with epithelial ovarian cancer every year, with the incidenceExpand
Frontline Maintenance Treatment for Ovarian Cancer
TLDR
Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer. Expand
Mitochondrial integration and ovarian cancer chemotherapy resistance.
TLDR
The cellular interactive regulatory network surrounding mitochondria is discussed, the mechanisms of tumor cell survival under chemotherapy under chemotherapy are elucidated, and potential means of interfering with mitochondrial function as a novel anti-cancer therapy are discussed. Expand
Clinicopathological predictors of chemoresponsiveness in epithelial ovarian cancer: a preliminary institutional study
TLDR
Complete response during treatment and optimal surgery significantly increases OS, CSS, and TTR, and preoperative CA125 and lymph node removal during surgery may be predictive of complete treatment response. Expand
Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
TLDR
It was demonstrated that adjuvant chemotherapy was unnecessary for patients with early-stage serous and endometrioid ovarian cancer after they underwent comprehensive staging surgery, and the age was associated with poor prognosis. Expand
Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
TLDR
Several membrane receptors associated with pivotal cellular processes and often aberrantly overexpressed in ovarian cancer cells have emerged as potential targets for receptor-mediated therapeutic strategies including specific agents and multifunctional delivery systems based on ligand-receptor binding. Expand
Ovarian Cancer: An Integrated Review.
TLDR
An overview of the risk factors, modifiable and non-modifiable, for ovarian cancer as well as prevention, diagnostic, treatment, and long-term survivorship concerns are provided. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Recent progress in the diagnosis and treatment of ovarian cancer
TLDR
New targeted biologic agents, particularly those involved with the vascular endothelial growth factor pathway and those targeting the poly (ADP‐ribose) polymerase (PARP) enzyme, hold great promise for improving the outcome of ovarian cancer. Expand
Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube
TLDR
A significant proportion of women treated for platinum-resistant/refractory ovarian, fallopian tube, or peritoneal carcinoma received therapy within the last few months of life with little clinical benefit, and disease progression on 2 consecutive lines of therapy should be used as a guide to discontinue cytotoxic treatment. Expand
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
TLDR
Selumetinib is well tolerated, and is active in the treatment of recurrent low-grade serous carcinoma of the ovary or peritoneum, and the findings suggest that inhibitors of the MAPK pathway warrant further investigation in these patients. Expand
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
TLDR
A signature of predictive markers, including low HER2 expression, predicts response in the first study of a hormonal agent in a preselected group of ER-positive ovarian cancer patients. Expand
Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube
  • J. Dietl
  • Medicine
  • Archives of Gynecology and Obstetrics
  • 2013
TLDR
Given the lack of suitable screening or early detection strategies for ovarian cancer, post-reproductive salpingectomy deserves serious consideration as a prophylactic intervention that will likely confer significant protection against an often deadly disease. Expand
Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon.
TLDR
Models to predict optimal surgical outcomes based only on tumor and patient characteristics will be highly practice-dependent and their utility in selecting patient for non-traditional primary approach to ovarian cancer must be looked at cautiously. Expand
A phase 3 trial of bevacizumab in ovarian cancer.
TLDR
In patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months, higher than the average for women with ovarian cancer. Expand
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
  • M. Bookman, M. Brady, +13 authors L. M. Roth
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction as well as survival analyses of groups defined by size of residual disease. Expand
Hereditary gynaecological malignancies: advances in screening and treatment
TLDR
How the molecular genetics is tailoring the manner in which these diseases are diagnosed and potentially treated is explained. Expand
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
TLDR
Bvacizumab has single-agent activity in patients with platinum-resistant EOC or PSC and a higher than expected incidence of GIP was noted in these heavily pretreated patients. Expand
...
1
2
3
4
5
...